Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Odyssey Therapeutics received a “Moderate Buy” consensus rating from six brokerages, with five buy ratings and one hold; the average 1-year price target is $32.00.
• Recent analyst actions were mixed: Wedbush and JPMorgan started coverage with bullish ratings, while Zacks moved to hold and Wall Street Zen cut the stock to sell.
• The company’s latest earnings missed estimates sharply, reporting ($6.77) EPS versus expectations of ($1.31), even as the stock traded up 3.6% to $18.22.

Shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $32.00.

A number of research firms have weighed in on ODTX. Zacks Research raised Odyssey Therapeutics to a "hold" rating in a research note on Wednesday, June 3rd. Wall Street Zen cut shares of Odyssey Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 20th. Wedbush assumed coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $30.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set an "overweight" rating on the stock. Finally, JPMorgan Chase & Co. started coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an "overweight" rating and a $26.00 price target on the stock.

Odyssey Therapeutics Trading Up 3.6%

ODTX opened at $18.22 on Wednesday. Odyssey Therapeutics has a twelve month low of $15.10 and a twelve month high of $20.30. The stock's 50-day simple moving average is $17.41.

Odyssey Therapeutics (NASDAQ:ODTX - Get Free Report) last released its earnings results on Wednesday, June 17th. The company reported ($6.77) earnings per share for the quarter, missing analysts' consensus estimates of ($1.31) by ($5.46).

Insider Activity at Odyssey Therapeutics

In other Odyssey Therapeutics news, Director Nan (Ln) Li purchased 1,111,111 shares of Odyssey Therapeutics stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the completion of the transaction, the director owned 3,333,516 shares of the company's stock, valued at $60,003,288. This trade represents a 50.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dimension Capital Ii, L.P. purchased 1,111,111 shares of the firm's stock in a transaction on Friday, May 8th. The stock was acquired at an average cost of $18.00 per share, with a total value of $19,999,998.00. Following the transaction, the director directly owned 3,333,516 shares in the company, valued at $60,003,288. This trade represents a 50.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 4,183,777 shares of company stock valued at $75,319,986 over the last ninety days.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source